TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03772223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 80/90 µg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (Budesonide metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 80 µg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (Budesonide metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 80 µg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (Budesonide metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 80 µg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (Budesonide metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 80 µg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (Budesonide metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 80 µg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (Budesonide metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 80 µg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C (Albuterol Sulfate metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 90 µg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C (Albuterol Sulfate metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 90 µg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C (Albuterol Sulfate metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 90 µg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C (Albuterol Sulfate metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 90 µg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C (Albuterol Sulfate metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 90 µg).
Study: NCT02464384

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Venipuncture, ultrasound, MRI, x-ray
Description: Collection of blood samples and ultrasound / MRI and x-ray examination
Study: NCT03772223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C (Albuterol Sulfate metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 90 µg).
Study: NCT01914380

Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Patients will be followed-up for 24 months
Study: NCT01251809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oncaspar
Description: 2000 U/m2 BSA, single infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rASNase
Description: 500, 1000 or 1500 U/m2 BSA single infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rASNase
Description: 500, 1000 or 1500 U/m2 BSA single infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rASNase
Description: 500, 1000 or 1500 U/m2 BSA single infusion
Study: NCT03572985

Intervention type: OTHER
Group type: OTHER
Intervention: Road-tracking test
Description: Driving with simulator program for SDLP measurement

Intervention type: OTHER
Group type: OTHER
Intervention: Road-tracking test
Description: Driving with simulator program for SDLP measurement

Intervention type: OTHER
Group type: OTHER
Intervention: Road-tracking test
Description: Driving with simulator program for SDLP measurement

Intervention type: OTHER
Group type: OTHER
Intervention: Road-tracking test
Description: Driving with simulator program for SDLP measurement

Intervention type: OTHER
Group type: OTHER
Intervention: Car-following test
Description: Driving with simulator program for DCV measurement

Intervention type: OTHER
Group type: OTHER
Intervention: Car-following test
Description: Driving with simulator program for DCV measurement
Study: NCT00085735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Craniospinal Irradiation
Description: Undergo craniospinal Irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Craniospinal Irradiation
Description: Undergo craniospinal Irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Craniospinal Irradiation
Description: Undergo craniospinal Irradiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Craniospinal Irradiation
Description: Undergo craniospinal Irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Craniospinal Irradiation
Description: Undergo craniospinal Irradiation
Study: NCT03572985

Intervention type: OTHER
Group type: OTHER
Intervention: Car-following test
Description: Driving with simulator program for DCV measurement

Intervention type: OTHER
Group type: OTHER
Intervention: Car-following test
Description: Driving with simulator program for DCV measurement

Intervention type: OTHER
Group type: OTHER
Intervention: Harsh-braking test
Description: Driving with simulator program for BRT measurement

Intervention type: OTHER
Group type: OTHER
Intervention: Harsh-braking test
Description: Driving with simulator program for BRT measurement

Intervention type: OTHER
Group type: OTHER
Intervention: Harsh-braking test
Description: Driving with simulator program for BRT measurement

Intervention type: OTHER
Group type: OTHER
Intervention: Harsh-braking test
Description: Driving with simulator program for BRT measurement
Study: NCT04169373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Upadacitinib tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib tablet administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Upadacitinib tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib tablet administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for upadacitinib tablet administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for upadacitinib tablet administered orally
Study: NCT02874807

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04720482

Intervention type: DIAGNOSTIC_TEST
Intervention: Somatosensory Evoked Potentials
Description: SSEP performed bilaterally with stimulation of the median nerve

Intervention type: DIAGNOSTIC_TEST
Intervention: Automated Pupillometry
Description: PLR quantified as NPi using a handheld automated pupillometer
Study: NCT04515693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 Minutes Walking Test
Description: A walkway of 12 meters will be marked with one cone at each end. The patient will be instructed to walk back and forth as many times as possible in six minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 Minutes Walking Test
Description: A walkway of 12 meters will be marked with one cone at each end. The patient will be instructed to walk back and forth as many times as possible in six minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 Minutes Walking Test
Description: A walkway of 12 meters will be marked with one cone at each end. The patient will be instructed to walk back and forth as many times as possible in six minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 Minutes Walking Test
Description: A walkway of 12 meters will be marked with one cone at each end. The patient will be instructed to walk back and forth as many times as possible in six minutes.
Study: NCT01864538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: 480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.
Study: NCT04543994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remestemcel-L
Description: An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remestemcel-L
Description: An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT00934570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and standard exercise
Description: Metformin 1500 mg daily for 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Intensive exercise
Description: Metformin 1500 mg daily for 2 years

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Standard exercise
Description: Standard exercise

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Intensive exercise
Description: Placebo Intensive exercise
Study: NCT02562560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral imaging (MRI, PET-FDG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral imaging (MRI, PET-FDG)
Study: NCT03586128

Intervention type: DRUG
Intervention: PrEP
Description: PrEP will be introduced into clinics according to Uganda national guidelines using a stepped wedge design. Uganda guidelines recommend any tenofovir disoproxil fumarate (TDF) containing medication be used for PrEP; this includes emtricitabine (FTC)/TDF, lamivudine (3TC)/TDF or TDF alone.

Intervention type: DRUG
Intervention: ART
Description: ART medication will be provided according to Uganda national guidelines for persons living with HIV.
Study: NCT04509349

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Altering Current Stimulation
Description: The participant will wear an electrode cap with 5 gel-filled cup HD electrodes arranged in a 4 x 1 montage.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial Altering Current Stimulation
Description: The participant will wear an electrode cap with 5 gel-filled cup HD electrodes arranged in a 4 x 1 montage.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham tACS
Description: 2 saline sponge electrodes will be attached to the upper arm contralateral to hand attached to the accelerometer.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tACS
Description: 2 saline sponge electrodes will be attached to the upper arm contralateral to hand attached to the accelerometer.
Study: NCT00865540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone acetate 1%
Description: 1 drop every 8h two days before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine 0.4%
Description: 1 drop every 8h two days before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nepafenac 0.1%
Description: 1 drop every 8h two days before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylcellulose 0.5%
Description: 1 drop every 8h two days before surgery
Study: NCT01882608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health Telemetry (MHT)
Description: Ecological momentary assessment (EMA) focuses on using data collected from subjects living their daily lives in their natural environments using minimally invasive techniques to improve the quality of the data collected. MHT is an evolution of EMA. MHT was developed at Sunnybrook in partnership with the University of Toronto; it uses cell phones to collect self-report data on symptoms of illness and then transmit it in real-time to a central database. Principal advantages of MHT over EMA include the ability to time- and date-stamp data, thus eliminating retrospective record completion, and the ability to observe and monitor data flow in real-time, without having to wait for participants to upload or deliver the data (e.g., at their next doctors' appointment).
Study: NCT03383016

Intervention type: OTHER
Intervention: Lifestyle questionnaires

Intervention type: DIAGNOSTIC_TEST
Intervention: Prostate Biopsy
Description: Possible follow-up by an urologist at 1 year and 2 years after recruitment. After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer.
Study: NCT05390619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 50% dose of photodynamic therapy
Description: Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 50% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 70% dose of photodynamic therapy
Description: Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 70% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2.
Study: NCT03848182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered on days 1, 8, 15 every 28 days
Study: NCT03875898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 150 g bread fortified (15 g mix fibre)
Description: Daily consumption of 150g of a bread fortified in fibre mix (15g) during eight weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 150 g unfortified bread
Description: Daily consumption of 150g of an usual bread in fibre-unfortified bread during eight weeks
Study: NCT00837109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Veteran Nightmare Treatment
Description: Veteran Nightmare Treatment Using Imagery Rescripting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Treatment-as-usual in the Trauma Recovery Program (that does not specifically target PTSD symptoms)
Study: NCT00429403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: 3.6 mg subcutaneous injection 1 week before the start of chemotherapy, then once a month until 3 weeks after the last chemotherapy dose.
Study: NCT03976037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Women randomized to either vaginal or buccal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of vaginal or buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~vaginal or Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Women randomized to either vaginal or buccal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of vaginal or buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~vaginal or Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated.
Study: NCT02466152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 Topical Cream
Description: GSK2894512 will be supplied as white to off-white topical cream in doses of 2.0% (20 milligrams/gram \[mg/g\]) and 1.0% (10 mg/g)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 Topical Cream
Description: GSK2894512 will be supplied as white to off-white topical cream in doses of 2.0% (20 milligrams/gram \[mg/g\]) and 1.0% (10 mg/g)
Study: NCT01499420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL112 (reconstituted high density lipoprotein)
Description: Single escalating intravenous doses of CSL112

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous doses of normal saline (0.9%)
Study: NCT04570735

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI
Study: NCT03958162

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung biopsy
Description: transbronchial lung cryobiopsy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung biopsy
Description: transbronchial lung cryobiopsy
Study: NCT02554123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E ointment application
Description: Vitamin E ointment application. Every 12 hours during 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaseline ointment application
Description: Vaseline ointment application. Every 12 hours during 7 days.
Study: NCT02486198

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1. For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), equal saline as placebo should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~2. For patients who discontinue oxaliplatin-based chemotherapy, equal saline as placebo should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM
Description: 1. For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), monosialotetrahexosylganglioside sodium injection(40mg for chemotherapy of every 2 weeks or 60mg for chemotherapy of every 3 weeks)should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~2. For patients who discontinue oxaliplatin-based chemotherapy, equal monosialotetrahexosylganglioside sodium injection should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin-based chemotherapy
Description: chemotherapy contains oxaliplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxaliplatin-based chemotherapy
Description: chemotherapy contains oxaliplatin
Study: NCT02707367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Roadmap (RR) Wave 1
Description: A web-based tool that provides guidance for implementing Person-Centered Recovery Planning. There are 3 components:~1. Online module for service providers: A self-paced online module with interactive exercises, audio/video case studies, self-assessment, handouts, and collaborative materials designed for use with clients.~2. Online module for people in recovery: A self-paced online module with interactive exercises, case studies, self-assessment, informational handouts, and collaborative materials to be completed with providers.~3. Coaching \& Support Center: A multimedia resource for providers with online coaching, a community of practice, and a resource library.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Roadmap (RR) Wave 2
Description: A web-based tool that provides guidance for implementing Person-Centered Recovery Planning. There are 3 components:~1. Online module for service providers: A self-paced online module with interactive exercises, audio/video case studies, self-assessment, handouts, and collaborative materials designed for use with clients.~2. Online module for people in recovery: A self-paced online module with interactive exercises, case studies, self-assessment, informational handouts, and collaborative materials to be completed with providers.~3. Coaching \& Support Center: A multimedia resource for providers with online coaching, a community of practice, and a resource library.
Study: NCT04245007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Doing fasting 2 days a week within 8 weeks
Study: NCT05220527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone plus hyruan
Description: triamcinolone plus hyruan injections, one time per week, for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitagen plus hyruan
Description: vitagen plus hyruan injections, one time per week, for 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline plus hyruan
Description: normal saline plus hyruan injections, one time per week, for 3 weeks